Adalimumab in rheumatoid arthritis treatment.docx
《Adalimumab in rheumatoid arthritis treatment.docx》由会员分享,可在线阅读,更多相关《Adalimumab in rheumatoid arthritis treatment.docx(14页珍藏版)》请在冰豆网上搜索。
![Adalimumab in rheumatoid arthritis treatment.docx](https://file1.bdocx.com/fileroot1/2023-1/23/9300b199-14f2-4bad-a3e3-e1ae87cc60d2/9300b199-14f2-4bad-a3e3-e1ae87cc60d21.gif)
Adalimumabinrheumatoidarthritistreatment
Adalimumabinrheumatoidarthritistreatment:
asystematicreviewandmeta-analysisofrandomizedclinicaltrials
MarinaAmaraldeÁvilaMachadoI,*;AlessandraAlmeidaMacielI;LíviaLovatoPiresdeLemosII;JulianaOliveiraCostaI;AdrianaMariaKakehasiIII;EliIolaGurgelAndradeIV;MariangelaLealCherchigliaV;FranciscodeAssisAcurcioVI
IPost-GraduationPrograminPublicHealth,SchoolofMedicine,UniversidadeFederaldeMinasGerais,BeloHorizonte,MG,Brazil
IIPost-GraduationPrograminMedicationsandPharmaceuticalCare,SchoolofPharmaceuticalSciences,UniversidadeFederaldeMinasGerais,BeloHorizonte,MG,Brazil
IIIDepartmentofMusculoskeletalSystem,SchoolofMedicine,UniversidadeFederaldeMinasGerais,BeloHorizonte,MG,Brazil
IVPost-GraduationPrograminDemographics,UniversidadeFederaldeMinasGerais,BeloHorizonte,MG,Brazil
VPost-GraduationPrograminPublicHealth,UniversidadedeSãoPaulo,SãoPaulo,SP,Brazil
VIPost-GraduationPrograminAnimalSciences,SchoolofVeterinaryMedicine,UniversidadeFederaldeMinasGerais,BeloHorizonte,MG,Brazil
ABSTRACT
Sincethediscoveryoftheroleoftumornecrosisfactorinthephysiopathologicalprocessofrheumatoidarthritis,fivedrugsthatblockthiscytokinehavebeenusedastherapeuticoptions.Toevaluatetheefficacyandsafetyofadalimumabinthetreatmentofrheumatoidarthritisweperformedasystematicreviewandmeta-analysisofrandomizedcontrolledtrials.AsearchofrelevantstudiesinMedline(throughPubMed)andLILACSinJune2011wascarriedout.Studyselection,datacollectionandanalysiswereperformedinpairsandindependentlybytworeviewersandbyathirdreviewerincasesofdisagreement.Themeta-analysiswasperformedusingthesoftwareReviewManager® 5.1usingtherandomeffectsmodel.Elevenarticlesrelatedtoadalimumabwereincludedandconsideredninestudieswith3461patients.Tenstudiesshowedlowriskofbiasregardingtheblindingofparticipantsandpersonnelandblindingofoutcomeassessment.Patientswhoreceivedthecombinationtreatmentofadalimumabandmethotrexateshowedbetterefficacyresultsandlowerradiographicprogressionwhencomparedtoplacebo+methotrexatein24-104weeks.Patientswhoreceivedadalimumabasmonotherapyshowedbetterefficacyoutcomeswhencomparedtoplaceboin24and26weeks.Theresultsofthemeta-analysesofadverseeventswerenotstatisticallysignificant,exceptforreactionsattheinjectionsite,whichfavoredthecontrolgroup.AdalimumabefficacywasdemonstratedinmonotherapyandwhenassociatedtoaDMARD,buttheevidenceforcombineduseismorerobust.
Keywords:
Rheumatoidarthritis;Adalimumab;Tumornecrosisfactor;Systematicreview;Meta-analysis
Introduction
Evidence-basedMedicineistheconscientious,explicitandsensibleuseofbestevidencefordecision-makinginpatientcare.Thepracticeofevidence-basedMedicineintegratestheindividualexperienceofthephysicianwiththebestevidenceavailablethroughsystematicresearch.1
SystematicreviewsareconsideredLevelIevidenceandhavestringentmethodsthatdecreasetheoccurrenceofbiaseswhencomparedtonarrativereviews.2 Thebenefitsofthemonoclonalantibodyadalimumabinthecontrolofrheumatoidarthritis(RA)havebeenwidelyreportedintheliteratureand,inBrazil,thisisthesecondmostuseddrugofthisclassofbiologicalagentsforthetreatmentofthisdisease.3-5 Theannualcostofthistreatmentishigh,beingestimatedinBrazilatR$71,117.00andwitharatioofincrementalcost-effectivenessperquality-adjustedlifeyear(QALY),whencomparedtotherapywithmethotrexate(MTX),ofR$628.124,00.6 Thishighcostemphasizestheimportanceofsystematizationofalltheevidenceavailabletoaiddecision-makinginhealthcare.
RAisasystemicinflammatory,chronicandprogressivediseaseofunknownetiologythataffectsthesynovialmembraneofjoints,leadingtocartilageandbonedestruction.Thisautoimmunedisorderaffectsthejoints,ofteninthehandsandfeet,onbothsidesequallyandsymmetrically.3,7 Theprevalenceisestimatedat0.5-1.0%ofthepopulationandismorefrequentinwomen,accordingtostudiesperformedintheUnitedStates,EuropeandBrazil.8,9
ThecareofpatientswithRAincludestheuseofdiseasemodifyingantirheumaticdrugs(DMARDs),nonsteroidalantiinflammatorydrugs(NSAIDs)andcorticosteroids,inadditiontonon-pharmacologicaltreatmentsuchasoccupationaltherapyandphysicaltherapy.10 BiologicalDMARDsrepresentabreakthroughintherapyandRAandhavebeenindicatedincaseswherepatientsdonotrespondtoconventionaltreatment.
Thetumornecrosisfactor(TNF)blockersadalimumab,etanercept,infliximab,certolizumabandgolimumabareincludedinthisclass.3,10,11
Aimingtocontributetothepracticeofevidence-basedMedicine,weperformedasystematicreviewandmeta-analysisofrandomizedcontrolledtrialstoevaluatetheefficacyandsafetyofAdalimumabinthetreatmentofRA.
Methods
Thisstudyispartofasystematicreviewofrandomizedcontrolledtrialsontheefficacyandsafetyofthedrugsadalimumab,etanercept,infliximabandrituximabinthetreatmentofrheumatoidarthritis.
Eligibilitycriteria
RandomizedcontrolledtrialswritteninPortuguese,EnglishandSpanishwereselectedforthereview.WeconsideredcomparisonsofAdalimumab40mgonceevery15daysasmonotherapyorcombinedwithDMARDsvs.controlgroupinpatientswithrheumatoidarthritisdiagnosisaccordingtotherevisedcriteriaoftheAmericanCollegeofRheumatologyandactivedisease.12
Articlesearch
ThesearchforstudieswascarriedoutintheMedlinedatabase(throughPubmed)andLILACSinJune2011andsupplementedbymanualsearchinginreferencesofsystematicreviewsandthestudiesthatwerefound.Thesearchstrategyconsistedofthefollowingwords:
rheumatoidarthritis,monoclonalantibodies,D2E7antibody,Humira®.ThesearchinPubmedwasstructuredfromMesh(MedicalSubjectHeadings)termsandasensitivesearchwasperformedforrandomizedcontrolledtrials.
Studyselectionanddatacollection
Studyselectionwascarriedoutbyanalysisofthetitlesandabstractsofstudiesselectedbythesearch.Datawerecollectedusingastandardizedform.
Tworeviewersindependentlyassessedandextracteddatafromeachstudyanddisagreementswereresolvedbyconsensusorbyathirdreviewer.Dataoncharacteristicsofthestudydesignandthepopulation,durationofdisease,previousorconcomitantuseofDMARDs,interventionandoutcomeswerecollectedforeachtrial.
TheprimaryoutcomewastheACR20responsedefinedbytheAmericanCollegeofRheumatology(ACR).ACR20responseoccurswhenthereisadecreasedof20%inthecountofjointswithpainandedemaandimprovementin3ofthe5variables:
overallassessmentbythepatientandphysician,pain,HealthAssessmentQuestionnaire(HAQ)scaleandacutephaseinflammatorymarkers(C-reactiveproteinorerythrocytesedimentationrate-ESR).13 ThesecondaryoutcomeswereACR50andACR70responses,inwhichthereare50%and70%improvementinthesameparameters,inadditiontofunctionality,measuredbytheHAQscale,radiographicoutcomes,losstofollow-upandsafety.Theauthors,ifnecessary,werecontactedtoprovideadditionalinformation.
Methodologicalqualityandriskofbias
Theassessmentofmethodologicalqualityandriskofbiaswasperformedindependentlybytworeviewerswithaccesstotheauthor'sname,institutionandthejournalthatpublishedthestudyanddisagreementswereresolvedbyconsensus.QualityassessmentbythemodifiedJadadscaleandriskofbiasassessmentproposedbytheCochraneCollaborationwereemployed.Thesetoolsassessmethodologicalaspects,suchasrandomization,blindingandlossofparticipants.ThemodifiedJadadscalescoresclinicaltrialsfrom0-6andthehigherthescore,thebetterthemethodologicalquality.14,15
Meta-analysis
Themeta-analysiswasperformedusingtheReviewManager® 5.1software.Weusedtheweighteddifferenceinmeansforcontinuousoutcomesandrelativeriskfordichotomousdata,bothconsideringaconfidenceintervalof95%.
Thepresenceofheterogeneitybetweenstudieswasconsideredapremiseandthereforetherandomeffectsmodelwasapplied.StatisticalheterogeneitywasconsideredifP<0.10forthechi-squaretestandI2 >40%andinthosecases,thepotentialfactorsthatinfluencedthisphenomenonwereinvestigated.16
Results
Thesearchforstudiesofthefourdrugs(Adalimumab,Etanercept,InfliximabandRituximab)resultedin3620articlesinPubmedand84inLILACS,aswellasninearticlesfoundbymanualsearch.ElevenarticlesrelatedtoAdalimumabwereincludedandconsideredninestudieswith3461patients(Fig.1).
Studycharacteristics
SevenstudiesevaluatedgroupsofpatientstreatedwithAdalimumab(ADA)40mgevery2weekscombinedwithsomeDMARDsvs.DMARDsasmonotherapy(plusplacebo):
insixstudiespatientsusedMTXandintheSTARstudysubjectsreceivedsomeDMARDs,amongthemMTX,chloroquine,hydroxychloroquine,leflunomide,parenteralgold,oralgoldcompounds,sulfasalazine,oranycombinationofthese.17 Mostpatients(82.1%groupADA+DMARDsand84.9%groupplacebo+DMARDs)usedoneormoreDMARDsduringthestudyandMTXwasthemostcommon(56.0%groupADA+DMARDsand62.6%groupplacebo+DMARDs).TwotrialswereperformedingroupsusingADA40mgevery2weeksasmonotherapycomparedtoplacebo.OnlythePREMIERstudyincludedarmsofcomparisonbetweenADAmonotherapyvs.MTXmonotherapy.18
PatientshadactiveRAinallstudies.ThestudyGUEPARDdefinedactivediseasebyDAS28(diseaseactivityscore)g